Effectiveness and safety of obinutuzumab in primary membranous nephropathy

Overview

Obinutuzumab shows high clinical remission rates in patients with primary membranous nephropathy (PMN). The study reports a 95.74% overall clinical remission rate after 24 months of treatment.

Background

Primary membranous nephropathy (PMN) is a significant cause of nephrotic syndrome and can lead to end-stage kidney disease. Traditional treatments often have substantial side effects and variable efficacy. Obinutuzumab, a type II anti-CD20 monoclonal antibody, offers a promising alternative with enhanced B-cell depletion capabilities.

Data Highlights

Key Findings

• 95.74% of PMN patients achieved clinical remission after 24 months of obinutuzumab therapy.
• 100% clinical remission rate was observed in the Initial therapy group.
• The Refractory group had a 96.88% clinical remission rate.
• All anti-PLA2R antibody-positive patients showed declining antibody levels post-treatment.
• 68.4% of patients attained complete immunological remission after therapy.

Clinical Implications

Obinutuzumab may be a viable treatment option for PMN patients, particularly those who are refractory to rituximab. The high remission rates suggest its potential role in managing this challenging condition.

Conclusion

Obinutuzumab demonstrates significant efficacy in treating PMN.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Treatment strategies for rituximab-resistant primary membranous nephropathy
2. Frontiers in Medicine, 2026 -- Obinutuzumab for refractory minimal change disease in obese patients
3. The ASCO Post, 2012 -- New Anti-CD20 Monoclonal Antibody Studied in B-cell Non-Hodgkin Lymphoma
4. The ASCO Post, 2019 -- Update on Newer Treatments in Non-Hodgkin Lymphomas
5. Glomerular Diseases (GD) – KDIGO, 2021 -- Guidelines
6. New England Journal of Medicine -- Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
7. Glomerular Diseases (GD) – KDIGO
8. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy | New England Journal of Medicine
9. https://io.nihr.ac.uk/wp-content/uploads/2025/12/30811-Obinutuzumab-for-Primary-Membranous-Nephropathy-V1.0-DEC2025-NON-CONF.pdf